Edgar Lomax Co. VA Lowers Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Edgar Lomax Co. VA reduced its stake in Bristol Myers Squibb by 55% during the first quarter, selling 107,640 shares and now holding 87,960 shares worth approximately $5.37 million.
• Bristol Myers Squibb reported $1.46 EPS for the last quarter, exceeding the consensus estimate of $1.07, with revenue reaching $12.27 billion compared to an expected $11.32 billion.
• The company declared a quarterly dividend of $0.62, reflecting a 5.1% dividend yield, and has a current payout ratio of 100%.

Edgar Lomax Co. VA reduced its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 55.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,960 shares of the biopharmaceutical company's stock after selling 107,640 shares during the period. Edgar Lomax Co. VA's holdings in Bristol Myers Squibb were worth $5,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Korea Investment CORP lifted its stake in shares of Bristol Myers Squibb by 2.0% in the 1st quarter. Korea Investment CORP now owns 2,038,026 shares of the biopharmaceutical company's stock valued at $124,299,000 after purchasing an additional 39,394 shares during the period. Qtron Investments LLC raised its position in Bristol Myers Squibb by 49.4% during the first quarter. Qtron Investments LLC now owns 30,794 shares of the biopharmaceutical company's stock worth $1,878,000 after acquiring an additional 10,177 shares during the period. Aptus Capital Advisors LLC raised its position in Bristol Myers Squibb by 8.6% during the first quarter. Aptus Capital Advisors LLC now owns 311,859 shares of the biopharmaceutical company's stock worth $19,020,000 after acquiring an additional 24,653 shares during the period. Northern Trust Corp raised its position in Bristol Myers Squibb by 5.3% during the first quarter. Northern Trust Corp now owns 25,974,504 shares of the biopharmaceutical company's stock worth $1,584,185,000 after acquiring an additional 1,316,144 shares during the period. Finally, FCG Investment Co acquired a new position in Bristol Myers Squibb during the first quarter worth $644,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Down 1.2%

BMY stock traded down $0.5880 during midday trading on Friday, reaching $47.8420. 11,600,362 shares of the company were exchanged, compared to its average volume of 13,263,239. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The stock's 50-day simple moving average is $47.09 and its 200 day simple moving average is $51.20. The company has a market cap of $97.38 billion, a price-to-earnings ratio of 19.29, a price-to-earnings-growth ratio of 2.47 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 100.00%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. Citigroup dropped their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Friday, August 1st. Daiwa America cut shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.